<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7129535/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Mechanisms of action and targets of potential treatment agents for SARS-CoV-2 infections.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Mechanism of action and targets</th>
   <th colspan="1" rowspan="1" id="0-1-.">Drugs</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>Inhibition of the RNA-dependent RNA polymerase</td>
   <td>Remdesivir 
    <br/>Favipiravir 
    <br/>Ribavirin 
   </td>
  </tr>
  <tr>
   <td>Inhibition of spike protein on SARS-CoV-2 (non-endosomal pathway)</td>
   <td>TMPRSS2 inhibitor (camostat mesylate)</td>
  </tr>
  <tr>
   <td>Inhibition of endosomal acidification (early endosomal pathway)</td>
   <td>Chloroquine, hydroxychloroquine (azithromycin is reported to greatly enhance the anti-SARS-CoV-2 activity of hydroxychloroquine)</td>
  </tr>
  <tr>
   <td>Inhibition of viral exocytosis</td>
   <td>Interferon-α 2a 
    <br/>Interferon-β 1b 
   </td>
  </tr>
  <tr>
   <td>Inhibition of papain-like protease and 3C-like protease</td>
   <td>Lopinavir/ritonavir</td>
  </tr>
  <tr>
   <td>Inhibition of cathepsin L and cathepsin B in host cells (late endosomal pathway)</td>
   <td>Teicoplanin (other glycopeptides including dalbavancin, oritavancin, and telavancin)</td>
  </tr>
  <tr>
   <td>Enhancement of the anti-SARS-CoV-2 activity of hydroxychloroquine</td>
   <td>Azithromycin</td>
  </tr>
 </tbody>
</table>
